Evidence map›Paper›PMID 42532517›Full record

ArticleEuropean journal of haematology2026

Dose-Adjusted Treatment With 7-Day Venetoclax Plus Azacitidine or Decitabine in Patients With Acute Myeloid Leukaemia.

Laurenz Steiner, Lina S Silva-Bermudez, Mahmoud Ghazal, Mohammed Abba, Catharina Gerhards, Georgia Metzgeroth, Alice Fabarius, Stefan Klein, Sebastian Kreil, Nanni Schmitt and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Laurenz SteinerDepartment of Haematology and Oncology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.ORCID https://orcid.org/0000-0002-4524-037X
Lina S Silva-BermudezGerman Red Cross Blood Service Baden-Württemberg-Hessen, Medical Faculty Mannheim, Institute of Transfusion Medicine and Immunology, Heidelberg University, Mannheim, Germany.ORCID https://orcid.org/0009-0006-6014-4470
Mahmoud GhazalDepartment of Haematology and Oncology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Mohammed AbbaDepartment of Haematology and Oncology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Catharina GerhardsMedical Faculty Mannheim, Institute for Clinical Chemistry, Heidelberg University, Mannheim, Germany.
Georgia MetzgerothDepartment of Haematology and Oncology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Alice FabariusDepartment of Haematology and Oncology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Stefan KleinDepartment of Haematology and Oncology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Sebastian KreilDepartment of Haematology and Oncology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Nanni SchmittDepartment of Haematology and Oncology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.ORCID https://orcid.org/0000-0003-3455-9606
Patrick WuchterGerman Red Cross Blood Service Baden-Württemberg-Hessen, Medical Faculty Mannheim, Institute of Transfusion Medicine and Immunology, Heidelberg University, Mannheim, Germany.ORCID https://orcid.org/0000-0001-9482-2870
Wolf-Karsten HofmannDepartment of Haematology and Oncology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Alexander StreuerDepartment of Haematology and Oncology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.ORCID https://orcid.org/0000-0002-3531-534X

Funding

Medical Faculty Mannheim, Heidelberg UniversityTorsten Haferlach Leukemia Diagnostics Foundation
6 · The paper itself

Abstract

Acute myeloid leukaemia (AML) in older or unfit patients is commonly treated with hypomethylating agents (HMA) plus venetoclax (VEN), but prolonged VEN exposure often causes substantial haematological toxicity. We retrospectively analysed 61 elderly AML patients treated with HMA + VEN for 7 (7d), 14 (14d) or > 14 days (> 14d) per cycle. Best overall response rate was 76% and did not differ significantly between schedules (p = 0.38). Median overall survival (OS) was numerically longer with 7d (28.4 months) than with 14d (11.4 months) or > 14d (6.7 months), although unadjusted differences were not significant (p = 0.23). At cycle level, the 7d schedule was associated with fewer infections and more complication-free cycles than both longer schedules, while bleeding events were similar. Grade 4 cytopenias and platelet transfusion requirements were also lower with 7d. In an adjusted Cox model, prior HMA exposure, non-favourable ELN 2024 risk and age ≥ 75 years were associated with inferior OS, whereas the 7d schedule remained associated with improved OS versus > 14d (HR 0.33, p = 0.03). Higher recent grade 4 neutropenia burden was independently associated with inferior OS. These findings suggest that abbreviated VEN exposure may improve tolerability without clear loss of efficacy in AML patients ineligible for intensive chemotherapy.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsLeukemia, Myeloid, AcuteAgedAged, 80 and overAzacitidineBridged Bicyclo Compounds, HeterocyclicDecitabineDrug Administration ScheduleFemaleHumansMaleRetrospective StudiesSulfonamidesTreatment OutcomeAzacitidineBridged Bicyclo Compounds, HeterocyclicDecitabineSulfonamidesvenetoclaxacute myeloid leukaemiadose‐adjusted treatmenthypomethylating agentsvenetoclax

Identifiers

PMID42532517
PMCPMC13643631

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.